The data collected included age, race, sex, best-corrected Snellen visual acuity, initial ocular symptom, involved tissue (choroid, retina-vitreous, orbit, eyelid, or conjunctiva), and lymphoma type (extranodal marginal zone B-cell lymphoma [MALT], diffuse large B-cell, follicular, or benign reactive lymphoid hyperplasia). Imaging studies performed (magnetic resonance imaging, computed tomography, or ultrasound) were recorded. Maximum tumor dimensions were recorded in millimeters and measured from ophthalmoscopy and ultrasound for intraocular lesions, magnetic resonance imaging or computed tomography for orbital lesions, slitlamp evaluation for conjunctival lesions, and external examination for eyelid lesions. The location of the tumor was classified according to quadrant involved (superior, inferior, medial, or lateral), coronal location (intraocular, muscle involvement, lacrimal gland, orbital fat, or eyelid), and axial location (anterior, midorbit, posterior, or intraocular). Previous ocular treatments and procedures (pars plana vitrectomy, incisional biopsy, excisional biopsy, or fine-needle aspiration biopsy) were recorded. The systemic status of the patient at the first visit was also recorded. Follow-up visits were scheduled at 2, 6, 12, and 24 months and then on a yearly basis. Follow-up information included visual acuity, funduscopy, Hertel exophthalmometry, Ishihara color plates, Humphrey visual field, response to therapy with local tumor status (completely regressed, partially regressed, stable, or local recurrence), systemic outcome (alive without systemic involvement, alive with systemic involvement, or dead), and complications of therapy (dry eye syndrome [defined as the presence of superficial punctate keratitis on slitlamp examination, tear film break-up test of <10 seconds, or abnormal results of the Schirmer test], radiation retinopathy, radiation papillopathy, radiation cataract, or radiation glaucoma) and their management.